Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow

Best PFS In Second Line Setting

The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.

Sanofi Lyon
Sanofi's Sarclisa is taking on the $6bn-a-year blockbuster Darzalex. • Source: Alamy

Sanofi has unveiled strong Phase III results for anti-CD38 targeted immunotherapy Sarclisa (isatuximab), as an addition to second-line therapy for multiple myeloma, which will help it gain a toehold in a highly competitive market.

The results strengthen its use case in this later-line setting ahead of gaining further approvals in earlier-stage disease. Updated results...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip